“It has truly been a privilege to work for Q-linea for over 15 years. I am pleased and honored that the major owners would like me to continue to contribute to the future development of Q-linea in a new role. I am proud of what we have accomplished so far, we have built a strong commercial foundation and I hope to see ASTar enter the US market before I step down. I look forward to seeing all the good Q-linea will do for patients with severe infections”, said Jonas Jarvius, CEO of Q-linea.

“Jonas has been instrumental in the development of Q-linea. The board and I will miss him as CEO and it is regrettable that he steps down. At the same time we see that his long experience and solid background can add valuable perspectives to the work of the board. Q-linea has built a strong foundation and now our search for a new CEO that can take the company through the next stage of commercialization begins,” said Erika Kjellberg Eriksson, Chairman of the board.